CTTH (CTT Pharmaceutical Holdings) Stock Based Compensation: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings Stock Based Compensation?

CTT Pharmaceutical Holdings CTTH -0.13% Stock Based Compensation is $0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

CTT Pharmaceutical Holdings's Stock Based Compensation for the six months ended in Dec. 2025 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

CTT Pharmaceutical Holdings Stock Based Compensation Related Terms

CTT Pharmaceutical Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for CTT Pharmaceutical Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTT Pharmaceutical Holdings Stock Based Compensation Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.31 0.24 0.00 0.00

CTT Pharmaceutical Holdings Semi-Annual Data
Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.31 0.24 0.00 0.00

CTT Pharmaceutical Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
CTT Pharmaceutical Holdings (CTTH) has a Stock Based Compensation of $0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CTT Pharmaceutical Holdings and its competitors.
Is CTT Pharmaceutical Holdings' Stock Based Compensation too high?
CTT Pharmaceutical Holdings' current Stock Based Compensation is $0.00 Mil.
How does CTT Pharmaceutical Holdings' Stock Based Compensation compare to BUDZ and SBFM?
CTT Pharmaceutical Holdings' Stock Based Compensation of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CTT Pharmaceutical Holdings and its competitors. CTT Pharmaceutical Holdings's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Stock Based Compensation is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.